MediMix’s Post

📣 In this first-of-its-kind study, we showed that #Immunotherapy could be used to prevent #Cancer. 🔊 We showed that Immunotherapy decreases secondary cancer by almost 70% (P<0.01). ⚡Our study has paved the way for a revolutionary approach: Preventative Immunotherapy, a promising new avenue in the battle against cancer. 🔔 Check out our abstract in the coming #ASCO24. Cleveland Clinic Merck Bristol Myers Squibb AstraZeneca Roche Jame Abraham, M.D. FACP American Society of Clinical Oncology (ASCO) #ASCO #Oncology #ClevelandClinic

Big ups to Russell C. Langan, MD, FACS, FSSO and RWJBarnabas Health for winning the 14th annual ACCC Innovator Awards which recognize visionary and compelling ideas in oncology from the ACCC! “In the 2 years following program implementation, 82 pancreatic cancers were detected from incidental findings with 65% of patients being diagnosed in earlier stages (stages I, II, and III), as well as instances of ampullary cancer, gallbladder cancer, and gastric cancer.” #defydisease https://lnkd.in/geeHnxAQ

𝗔𝗱𝘃𝗮𝗻𝗰𝗶𝗻𝗴 𝗥𝗲𝘀𝗲𝗮𝗿𝗰𝗵 𝗶𝗻 𝗥𝗲𝗰𝘂𝗿𝗿𝗲𝗻𝘁 𝗟𝗼𝘄-𝗚𝗿𝗮𝗱𝗲 𝗦𝗲𝗿𝗼𝘂𝘀 𝗢𝘃𝗮𝗿𝗶𝗮𝗻 𝗖𝗮𝗻𝗰𝗲𝗿 (𝗟𝗚𝗦𝗢𝗖) Today, we announced updated positive data from the Phase 2 RAMP 201 trial in recurrent LGSOC, which is one of the largest clinical trials ever conducted in this rare ovarian cancer. These results mark meaningful progress toward potentially offering a new combination therapy to patients in the U.S. The detailed findings will be presented today at the International Gynecologic Cancer Society (IGCS) Annual Meeting. 𝗟𝗲𝗮𝗿𝗻 𝗮𝗯𝗼𝘂𝘁 𝗮𝗹𝗹 𝘁𝗵𝗲 𝘂𝗽𝗱𝗮𝘁𝗲𝘀 𝗶𝗻 𝗼𝘂𝗿 𝗽𝗿𝗲𝘀𝘀 𝗿𝗲𝗹𝗲𝗮𝘀𝗲: https://lnkd.in/edcr6sSU #VerastemOnc ##LGSOC #IGCS2024 #OvarianCancer

Thomas Zindrick, CEO of Genelux, and Jane LeBlanc, RN, Director, Clinical Site Liaison at Genelux, delve into the intricacies of advanced therapies for platinum-resistant and refractory ovarian cancer (PRROC). Listen as they explore treatment methodologies, patient perspectives and how Genelux is playing a significant role in the future of ovarian cancer treatment. Watch the full video on the Company's YouTube page! https://loom.ly/Mvls6Pw #Stage4NeedsMore #CancerResearch #ClinicalTrials #OvarianCancerCare 

🌟 𝗡𝗲𝘄 𝗥𝗲𝗹𝗲𝗮𝘀𝗲: "𝗪𝗵𝗮𝘁’𝘀 𝗡𝗲𝘄 𝗗𝗼𝗰? 𝗶𝗻 𝗚𝗨 𝗖𝗮𝗻𝗰𝗲𝗿” 🌟 In our latest episode, Prof Emmanuel Seront and Prof Christof Vulsteke provide a detailed analysis of the KEYNOTE-B61 study, a significant leap forward in the treatment of non-clear cell renal cancer, as presented at ASCO. Discover how the combination of lenvatinib and pembrolizumab is setting new standards for patient care, showing promising results beyond its established success in endometrial and clear cell renal cancers. 👇 View all WND GU videos - link in the comments! #MediMix #GUCancer #RenalCancer #OncologyInnovation

Dr Rik Van Severen of University Hospitals Leuven reveals promising outcomes from a study on alpelisib combined with antihormonal therapy for hormone receptor-positive, HER2-negative metastatic breast cancer. With a clinical benefit rate of 26.3% and manageable side effects, this research marks a significant step forward for PIK3CA-mutated breast cancer treatment. Despite some discontinuations due to toxicity, the findings affirm alpelisib’s role as a next-generation therapy with a noteworthy safety profile. Discover these vital insights. 👇 For all SABCS 2023 videos, find the link in the comments! #SABCS2023 #BreastCancerResearch #Alpelisib #OncologyInnovation

Our vision for patients with ovarian cancer? 3D Predict™. With nearly 14,000 women dying from ovarian cancer last year alone and a 5-year survival rate of 50%, the need is critical. In the coming months, physicians will be able to order our 3D Predict test for newly diagnosed ovarian cancer patients prior to initiating chemotherapy. Make the first treatment the most effective one. See how it works: bit.ly/3DPredictVideo #Kiyatec #3DPredict #FightOvarianCancer #OvarianCancerAwareness #PrecisionOncology

Watch the insightful panel discussion about Ovarian Cancer moderated by Dr. Rohit Pai, an esteemed figure in oncology from ICTC Sion on the eve of Ovarian Cancer Day. Dr. Rohit Pai leads a distinguished panel of experts to explore the nuanced role of Bevacizumab & Rucaparib in the maintenance therapy landscape of ovarian cancer. Navigate through the complexities of ovarian cancer treatment strategies, shedding light on the optimal utilization of Bevacizumab & Rucaparib in maintenance therapy. Watch here - https://lnkd.in/dAgxb29F #ovariancancer #ovariancancerday #ovariancancerawareness #ovariancancerresearch #Ovarian #ovarianhealth #ictc #drrohitpai #indiancancertreatmentcentre #cancertreatmentcentre #cancertreatment #cancerawareness

Pancreatic cancer screenings hold great promise in detecting the disease at an earlier, more treatable stage. Learn more about what the screenings consist of and when you should consider speaking with your doctor. And for more information on pancreatic cancer screenings at CentraState: https://lnkd.in/exVu6s-s #PancreaticCancer #CanerScreenings

Until now, there have been no adequate easy early screening methods or diagnostic methods for detecting pancreatic cancer. For the first time ever, we now have the opportunity to offer individuals at high risk a unique early pancreatic cancer test. https://lnkd.in/e3jqjpsU #liquidbiopsy #pancreaticcancer